One Infusion. A Lifetime of Difference. Steve's Story.

Steve W. lived with hemophilia B almost all of his life. Managing it with weekly clotting factor infusions and the daily reality that comes with a lifelong bleeding disorder. Then he became the 52nd patient to receive Hemgenix® (Etranacogene dezaparvovec-drlb), the FDA-approved one-time gene therapy for hemophilia B, right here at the Barbara Ann Karmanos Cancer Institute in Detroit. The first and only independent cancer center in the U.S. to offer this treatment. This is his story: what life looked like before, what it was like receiving the treatment and what’s changed since. Learn more about Hemgenix at Karmanos: https://www.karmanos.org/karmanos/hem... #Hemgenix #HemophiliaB #GeneTherapy #KarmanosCancerInstitute #PatientStory #RareDisease #FactorIX